Despite cutaneous B-cell lymphoma often having a relatively indolent course and low mortality, it is often resistant to conventional therapy and frequently relapses. We describe a patient with widespread cutaneous B-cell lymphoma who was treated successfully with a recently approved chimeric monoclonal antibody directed against the CD20 antigen (rituximab) and the CD20-negative relapse that resulted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mjd.2002.108490 | DOI Listing |
Publication Analysis
Top Keywords
cutaneous b-cell
12
b-cell lymphoma
12
cd20-negative relapse
8
monoclonal antibody
8
relapse cutaneous
4
lymphoma anti-cd20
4
anti-cd20 monoclonal
4
antibody therapy
4
therapy despite
4
despite cutaneous
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!